Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

@article{Cassidy1999BioequivalenceOT,
  title={Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients},
  author={Jim Cassidy and Chris Twelves and David Cameron and William C. Steward and Ken O'Byrne and Duncan J. Jodrell and Ludger Banken and Timothy K. Goggin and David R. Jones and Brigitte Roos and Erine Bush and Erhard Weidekamm and Bruno G. Reigner},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1999},
  volume={44},
  pages={453-460}
}
Purpose: The objective of the study was to assess the bioequivalence of two tablet formulations of capecitabine and to explore the effect of age, gender, body surface area and creatinine clearance on the systemic exposure to capecitabine and its metabolites. Methods: The study was designed as an open, randomized two-way crossover trial. A single oral dose of 2000 mg capecitabine was administered on two separate days to 25 patients with solid tumors. On one day, the patients received four 500-mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

A multicenter phase II trial of Xeloda (capecitabine) in Paclitaxel-refractory metastatic breast cancer (abstract no. 476)

  • JL Blum, AU Budzur, +5 authors TA Grin
  • Proc Am Soc Clin Oncol
  • 1998
1 Excerpt

A multicenter phase II trial of XelodaTM ( capecitabine ) in Paclitaxel - refractory metastatic breast cancer ( abstract no . 476 )

  • JL Blum, AU Budzur, +4 authors C Brown
  • Proc Am Soc Clin Oncol
  • 1998

Similar Papers

Loading similar papers…